EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial

Kaiyang Ding, Hailing Liu, Lixia Sheng, Jie Ma, Xiaohui Zhang, Hongming Huang, Wei Shi, Hongling Peng, Lei Cao, Wei Wu, Jianyong Li, Lei Fan

European Journal of Cancer · 2025-01 · 214 · 115155

DOI: 10.1016/j.ejca.2024.115155 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2025-01. Verfasst von Kaiyang Ding und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Anhui Provincial Hospital, the First Affiliated Hospital of USTC, Hefei 230002, Anhui, China. Hauptthemen laut MEDLINE: Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized, Asparaginase. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Extranodal natural killer/T-cell lymphoma (ENKTCL) is almost always fatal after the failure of asparaginase. This phase II study aimed to investigate the efficacy and safety of tislelizumab combined with gemcitabine and oxaliplatin (Tisle-GemOx) in patients with ENKTCL failing asparaginase. METHODS: Eligible patients received Tisle-GemOx as initial induction for 6-8 cycles at 21-day intervals. Responders continued tislelizumab maintenance every two months for two years. The primary endpoint was the best complete response rate (CRR). RESULTS: As of September 2023, 32 patients were enrolled in our study. Among the 30 efficacy-evaluable patients, the best CRR was 60 %, meeting the primary efficacy endpoint. With a median follow-up of 22.6 months, the median progression-free survival (PFS) was 7.4 months and the 1-year PFS rate was 46.4 %. Subgroup analyses showed that shorter PFS was associated with previous lines of chemotherapy ≥ 2 (P = 0.034) and concomitant hemophagocytic lymphohistiocytosis (P = 0.040). Pseudo-progression was observed in three patients (10 %). The most common grade ≥ 3 toxicities were lymphopenia (25 %) and anemia (15.6 %). CONCLUSIONS: Tisle-GemOx exhibits promising anti-tumor activity and manageable toxicities as a salvage therapy for ENKTCL failing asparaginase. Further long-term follow-up is necessary to evaluate the durability of the response with tislelizumab maintenance in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedAsparaginaseLymphoma, Extranodal NK-T-CellGemcitabineOxaliplatinHumansMaleFemaleMiddle AgedAdultAgedYoung AdultProgression-Free Survival

Stichwörter der Autor:innen

AsparaginaseChemotherapyExtranodal NK/T-cell lymphomaHemophagocytic lymphohistiocytosisPD-1 blockade

Substanzen

DeoxycytidineAntibodies, Monoclonal, HumanizedAsparaginaseGemcitabineOxaliplatintislelizumab

Autor:innen und Institutionen

  • Department of Hematology, Anhui Provincial Hospital, the First Affiliated Hospital of USTC, Hefei 230002, Anhui, China.
  • Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personali…
  • Department of Hematology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China.
  • Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
  • Department of Hematology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu, China.
  • Department of Hematology, the Affiliated Hospital of Nantong University, Nantong 226006, Jiangsu, China.

Förderung

  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Ding, K., Liu, H., Sheng, L., Ma, J., Zhang, X., Huang, H., Shi, W., Peng, H., Cao, L., Wu, W., Li, J., & Fan, L. (2025). Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial. European Journal of Cancer, 214, 115155. https://doi.org/10.1016/j.ejca.2024.115155

Vancouver

Ding K, Liu H, Sheng L, Ma J, Zhang X, Huang H, et al. Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial. European Journal of Cancer. 2025;214:115155. doi:10.1016/j.ejca.2024.115155

BibTeX
@article{Ding2025,
  author = {Ding, Kaiyang and Liu, Hailing and Sheng, Lixia and Ma, Jie and Zhang, Xiaohui and Huang, Hongming and Shi, Wei and Peng, Hongling and Cao, Lei and Wu, Wei and Li, Jianyong and Fan, Lei},
  title = {Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {214},
  pages = {115155},
  doi = {10.1016/j.ejca.2024.115155}
}
Kostenlos starten →